Table 1 General characteristics of studies included in our meta-analysis for hemoglobin decline, severe anemia and ribavirin dose reduction or discontinuation
Year | First author | Design | N | Age (years) | Gender (% male) | Country | Ethnicity (%) | HCV-GT | GT1/4 (%) | HCV therapy | HIV (% on cART) |
|---|---|---|---|---|---|---|---|---|---|---|---|
2010 | Fellay [8] | GWAS | 1286 | 47.3 | 61.74 | USA | C (76.8), H (7.8), AA (15.4) | 1 | 100 | Peg- + RBV | No |
2010 | Thompson [10] | GWAS | 318 | 48.5 | 65 | USA | C (55), AA (45) | 1 | 100 | Peg-α2a + RBV | No |
2010 | Sakamoto [15] | Cross-sectional | 474 | 57.2 | 55.7 | Japan | A (100) | 1b, 2a/b, 3a | NR | Peg-α2a/2b + RBV | No |
2011 | Thompson [16] | Retrospective | 238 | 52 | 59 | Italy, USA | C (100) | 2, 3 | 0 | Peg-α2b + RBV | No |
2011 | Azakami [17] | Retrospective | 1002 | 58 | 53.9 | Japan | A (100) | 1, Others | NR | Peg-α2b + RBV | No |
2011 | Chayama [36] | NR | 94 | 57 | 55.3 | Japan | A (100) | 1 | 100 | Peg-α2b + RBV + TPV | No |
2011 | Kurosaki [18] | Retrospective | 132 | 57.5 | 37.9 | Japan | A (100) | 1b | 100 | Peg-α2a/2b + RBV | No |
2011 | Rallón [19] | Retrospective | 74 | 43 | 74 | Spain | NR | 1, 2, 3, 4 | 87 | Peg-α2a/2b + RBV | Yes (NR) |
2012 | Nishimura [20] | NR | 176 | 62 | 61.5 | Japan | A (100) | 1, 2 | NR | Peg-α2a/2b + RBV | No |
2012 | Naggie [21] | Retrospective | 161 | 42 | 75 | Spain | C (100) | 1, 2, 3, 4 | 70 | Peg-α2a/2b + RBV | Yes (84) |
2012 | Domingo [22] | Prospective | 73 | 46.8 | 58.9 | Spain | NR | 1, 3, 4 | 75.3 | Peg-α2a + RBV | Yes (91.8) |
2012 | Osinusi [23] | NR | 123 | 45.5 | 70.7 | Germany, USA | C (58.5), AA (30.9), other (10.6) | 1, 2, 3 | NR | Peg-α2a/2b + RBV | Yes (83.1) |
2012 | Miyamura [37] | Retrospective | 97 | 55.8 | 45.36 | Japan | A (100) | 1, 2 | NR | Peg-α2a + RBV | No |
2012 | Vidal [33] | Prospective | 113 | 40 | 74.3 | Spain | NR | 1, 2, 3, 4 | 61.6 | Peg-α2a/2b + RBV | Yes (84.1) |
2012 | Tsubota [24] | Prospective | 561 | 59.1 | 53.8 | Japan | A (100) | 1b | 100 | Peg-α2a/2b + RBV | No |
2013 | Rau [25] | Retrospective | 216 | NR | 64.8 | Switzerland | C (100) | 1, 2, 3 | NR | Peg-α + RBV | No |
2013 | Di Marco [26] | Prospective | 233 | 58.7 | 64 | Italy | NR | 1, 2, 3 | NR | Peg-α2b + RBV | No |
2013 | Ahmed [27] | Retrospective | 102 | 32.5 | 88.2 | Egypt | C (100) | 1, 4 | 100 | Peg-α2a/2b + RBV | No |
2013 | Ogawa [34] | Prospective | 292 | 62 | 46.2 | Japan | A (100) | 1 | 100 | Peg-α2b + RBV + TPV | No |
2013 | Scherzer [28] | Retrospective | 308 | 43.9 | 60.1 | Austria | C (100) | 1 | 100 | Peg-α2a + RBV | No |
2013 | Fujino [38] | Retrospective | 120 | NR | 45.8 | Japan | A (100) | 1b | 100 | Peg-α2a/2b + RBV | No |
2013 | D’Avolio [29] | Retrospective | 379 | 46 | 60.9 | Italy | C (94.9), AA (5.1) | 1, 2, 3, 4 | 56.2 | Peg-α2a/2b + RBV | No |
2013 | Clark [30] | Prospective | 193 | NR | 56.5 | Italy | NR | 1, 2, 3, 4 | 63.73 | Peg-α2a + RBV | No |
2013 | Seto [39] | NR | 60 | 49 | 68.3 | Hong Kong | A (100) | 6 | 0 | Peg-α2a/2b + RBV | No |
2013 | Nakagawa [40] | Cross-sectional | 300 | 57 | 51 | Japan | A (100) | 1, 2 | NR | Peg- + RBV | No |
2014 | Matsuura [31] | NR | 309 | 57 | 52 | Japan | A (100) | 1 | 100 | Peg-α2a/2b + RBV | No |
2014 | Rembeck [41] | Retrospective | 354 | 42 | 42 | Scandinavian | C (100) | 2, 3 | 0 | Peg-α2a + RBV | No |
2014 | Aghemo [35] | Retrospective | 69 | 57 | 67 | Italy | NR | 1 | 100 | Peg-α2a/2b + RBV + TPV | No |
2014 | Hwang [32] | Cross-sectional | 175 | 55.5 | 66.3 | Taiwan | NR | 1, others | 63.4 | Peg-α2a/2b + RBV | No |